NCT06709534 An Individualized Online Home-Based Exercise Program for Improving Symptoms in Gynecologic Cancer Survivors
| NCT ID | NCT06709534 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Malignant Female Reproductive System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-09-01 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests an individualized online home-based exercise program in gynecologic cancer survivors and its impact on gut microbiome (the bacteria and microorganisms that live in the digestive system) and symptoms such as pain, fatigue, sleep disturbance, depression, and cognitive impairment. These symptoms can significantly reduce the quality of life (QoL) and survival rate in this cancer population. Thus, promoting physical activity among cancer survivors may help mitigate these severe symptoms. Using online platforms such as Zoom can help participants access an individualized exercise program that meets their specific needs to engage in physical activity and decrease their symptom burden. Home-based exercise, by providing self-chosen time and location and low costs, can address some barriers to physical activity for cancer survivors. An individualized online home-based exercise program may be feasible, and may improve symptoms and quality of life in gynecologic cancer survivors.
Eligibility Criteria
Inclusion Criteria: * Women aged ≥ 18 years old * Previously diagnosed with gynecologic cancer (e.g., uterine, ovarian, cervical) * Completed cancer treatment (chemotherapy or chemoradiation) * Able to read and speak English * Do not meet recommended exercise levels as defined by The American College of Sports Medicine Exclusion Criteria: * History of metastatic or other primary cancer * Serious mental health conditions (e.g., bipolar disorder, schizophrenia, major depression) * Certain chronic diseases (e.g., muscular-skeletal diseases that limit mobility, autoimmune diseases, uncontrolled diabetes, hypertension, renal disease (creatinine \> 2.5 mg/dL) * Unable to read/speak English
Contact & Investigator
Zahra A Barandouzi, Ph.D.,MSN,RN
PRINCIPAL INVESTIGATOR
Emory University Hospital/Winship Cancer Institute
Frequently Asked Questions
Who can join the NCT06709534 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Malignant Female Reproductive System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06709534 currently recruiting?
Yes, NCT06709534 is actively recruiting participants. Contact the research team at zahra.barandouzi@emory.edu for enrollment information.
Where is the NCT06709534 trial being conducted?
This trial is being conducted at Atlanta, United States, Atlanta, United States, Atlanta, United States, Decatur, United States.
Who is sponsoring the NCT06709534 clinical trial?
NCT06709534 is sponsored by Emory University. The principal investigator is Zahra A Barandouzi, Ph.D.,MSN,RN at Emory University Hospital/Winship Cancer Institute. The trial plans to enroll 40 participants.